Summary Basis of Decision (SBD) for Istodax

Health Canada has issued a Notice of Compliance under the Notice of Compliance with Conditions Guidance to Celgene Inc. for the Istodax drug product. Based on Health Canada's review, the benefit/risk profile of Istodax is favourable for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma who are not eligible for transplant and have received at least one prior systemic therapy. Read more here.